
<!DOCTYPE html>
<html>
<head>
<meta charset="UTF-8">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<meta http-equiv="X-UA-Compatible" content="ie=edge">
<title>Markmap</title>
<style>
* {
  margin: 0;
  padding: 0;
}
#mindmap {
  display: block;
  width: 100vw;
  height: 100vh;
}
</style>
<link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/markmap-toolbar@0.17.0/dist/style.css">
<link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/katex@0.16.8/dist/katex.min.css">
</head>
<body>
<svg id="mindmap"></svg>
<script src="https://cdn.jsdelivr.net/npm/d3@7.8.5/dist/d3.min.js"></script>
<script src="https://cdn.jsdelivr.net/npm/markmap-view@0.17.0/dist/browser/index.js"></script>
<script src="https://cdn.jsdelivr.net/npm/markmap-toolbar@0.17.0/dist/index.js"></script>
<script>
window.WebFontConfig = {
  custom: {
    families: [
      "KaTeX_AMS","KaTeX_Caligraphic:n4,n7","KaTeX_Fraktur:n4,n7",
      "KaTeX_Main:n4,n7,i4,i7","KaTeX_Math:i4,i7","KaTeX_Script",
      "KaTeX_SansSerif:n4,n7,i4","KaTeX_Size1","KaTeX_Size2",
      "KaTeX_Size3","KaTeX_Size4","KaTeX_Typewriter"
    ],
    active: function() {
      window.markmap.refreshHook.call();
    }
  }
};
</script>
<script src="https://cdn.jsdelivr.net/npm/webfontloader@1.6.28/webfontloader.js" defer></script>
<script>
(() => {
  setTimeout(() => {
    const { markmap: Markmap, mm: markmapInstance } = window;
    const toolbar = new Markmap.Toolbar();
    toolbar.attach(markmapInstance);
    const toolbarElement = toolbar.render();
    toolbarElement.style.position = 'absolute';
    toolbarElement.style.bottom = '20px';
    toolbarElement.style.right = '20px';
    document.body.append(toolbarElement);
  });

  ((getMarkmap, getOptions, root, jsonOptions) => {
    const markmap = getMarkmap();
    window.mm = markmap.Markmap.create(
      "svg#mindmap",
      (getOptions || markmap.deriveOptions)(jsonOptions),
      root
    );
  })(() => window.markmap, null, {"content":"Breast Cancer","children":[{"content":"\n<p data-lines=\"1,2\">Prevention in High Risk</p>","children":[{"content":"Elevated IBIS &gt;20%","children":[{"content":"IBIS 10-year &gt;= 5%","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Annual MMG and MRI (Minimum age 30 and 25 respectively)","children":[],"payload":{"lines":"4,5"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Chemoprevention with Tamoxifen (20mg vs babytam) or Raloxifen or AI (if intolerant to SERM)","children":[],"payload":{"lines":"5,6"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Similar recommendations for GAIL 5-year &gt;= 1.7%","children":[],"payload":{"lines":"6,7"}}],"payload":{"lines":"3,7"}},{"content":"IBIS 10-year &lt; 5%","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Annual MMG and MRI (Minimum age 30 and 25 respectively)","children":[],"payload":{"lines":"8,9"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Chemoprevention on case-by-case basis (if risk is thought elevated)","children":[],"payload":{"lines":"9,10"}}],"payload":{"lines":"7,10"}}],"payload":{"lines":"2,10"}},{"content":"Germline mutation","children":[{"content":"Management per mutation. <a href=\"https://myriad.com/gene-table/\">Myriad Gene Table</a>","children":[],"payload":{"lines":"11,13"}}],"payload":{"lines":"10,13"}}],"payload":{"lines":"1,13"}},{"content":"\n<p data-lines=\"13,14\">Premalignant and High Risk Conditions</p>","children":[{"content":"LCIS","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Most require excisional biopsy","children":[],"payload":{"lines":"15,16"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Chemoprevention with Tamoxifen (20mg vs babytam per <strong>TAM001</strong>)","children":[],"payload":{"lines":"16,17"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Raloxifen or AI can be used (if intolerant to SERM)","children":[],"payload":{"lines":"17,18"}}],"payload":{"lines":"14,18"}},{"content":"ADH","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Some require excisional biopsy","children":[],"payload":{"lines":"19,20"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Chemoprevention with Tamoxifen (20mg vs babytam per <strong>TAM001</strong>)","children":[],"payload":{"lines":"20,21"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Raloxifen or AI can be used (if intolerant to SERM)","children":[],"payload":{"lines":"21,22"}}],"payload":{"lines":"18,22"}},{"content":"DCIS","children":[{"content":"ER +ve","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Surgical Excision is strongly recommended. Mastectomy VERSUS BCT","children":[],"payload":{"lines":"24,25"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Oncotype DCIS or DecisionRT post BCS can omit RT if low score","children":[],"payload":{"lines":"25,26"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Chemoprevention with Tamoxifen (20mg vs babytam per <strong>TAM001</strong>)","children":[],"payload":{"lines":"26,27"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Raloxifen or AI can be used (if intolerant to SERM per <strong>NSABP B-35</strong>)","children":[],"payload":{"lines":"27,28"}}],"payload":{"lines":"23,28"}},{"content":"ER -ve","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Surgical Excision is strongly recommended. Mastectomy VERSUS BCT","children":[],"payload":{"lines":"29,30"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> No distinct benefit in chemoprevention","children":[],"payload":{"lines":"30,41"}}],"payload":{"lines":"28,41"}}],"payload":{"lines":"22,41"}}],"payload":{"lines":"13,41"}},{"content":"\n<p data-lines=\"41,42\">Premenopausal HR+ HER2-</p>","children":[{"content":"\n<p data-lines=\"43,44\">STAGE I</p>","children":[{"content":"pT1a N0","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Adjuvant ET is category 2B but still discussed. Absolute DFS and BCSS benefit very small","children":[],"payload":{"lines":"45,46"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Can be considered for 2ry chemoprevention.","children":[],"payload":{"lines":"46,47"}}],"payload":{"lines":"44,47"}},{"content":"pT1b cN0 Grade I","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> TAILORx did not include this population. Can consider MammaPrint on case by case basis","children":[],"payload":{"lines":"48,49"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Adjuvant ET (AI versus SERM). OFS benefit is small","children":[],"payload":{"lines":"49,50"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> ET duration for 5 years (+/- 5 years per BCI or MP)","children":[],"payload":{"lines":"50,51"}}],"payload":{"lines":"47,51"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> pT1b cN0 Grade II/III and pT1c cN0","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Consider Oncotype / Mammaprint (TC) <strong>TAILORx</strong> and <strong>MINDACT</strong>","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> RS ≥26: Chemotherapy","children":[],"payload":{"lines":"53,54"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> RS 16-25 : Discuss Chemotherapy (individualized benefit)","children":[],"payload":{"lines":"54,55"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> ≤15 or less → No Chemotherapy","children":[],"payload":{"lines":"55,56"}}],"payload":{"lines":"52,56"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Adjuvant ET (AI versus SERM). OFS benefit is small","children":[],"payload":{"lines":"56,57"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> ET duration for 5 years (+/- 5 years per BCI or MP)","children":[],"payload":{"lines":"57,60"}}],"payload":{"lines":"51,60"}}],"payload":{"lines":"43,60"}},{"content":"\n<p data-lines=\"60,61\">STAGE II</p>","children":[{"content":"pT2 N0","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Send Oncotype/Mammaprint (TC)","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> RS ≥26: Chemotherapy","children":[],"payload":{"lines":"63,64"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> RS 16-25 : Discuss Chemotherapy (individualized benefit)","children":[],"payload":{"lines":"64,65"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> ≤15 or less → No Chemotherapy","children":[],"payload":{"lines":"65,66"}}],"payload":{"lines":"62,66"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Adjuvant ET (AI versus SERM) with Ovarian Suppression [Consider NAET for larger tumors]","children":[],"payload":{"lines":"66,67"}}],"payload":{"lines":"61,67"}},{"content":"pT1 N1, pT2 N1","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> For pT1c N0, consider Oncotype/Mammaprint (TC) [Consider NACT for larger tumors]","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> → Chemotherapy irrespective of RS","children":[],"payload":{"lines":"69,70"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Absolute benefit can be small, and can be offset with OFS","children":[],"payload":{"lines":"70,71"}}],"payload":{"lines":"68,71"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Adjuvant ET (AI versus SERM) with Ovarian Suppression [Consider NAET for larger tumors]","children":[],"payload":{"lines":"71,72"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> ET duration for 5 years (+/- 5 years per BCI or <a href=\"https://cts5-calculator.com/\">CTS5 Calculator</a>)","children":[],"payload":{"lines":"72,73"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Adjuvant Abemaciclib in high risk patient: pN2/3 OR pN1 with either T3 OR Grade III","children":[],"payload":{"lines":"73,74"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Adjuvant Olaparib in high-risk ER+ HER2- gBRCA1/2 (and PALB2) Stage II and III","children":[],"payload":{"lines":"74,75"}}],"payload":{"lines":"67,75"}},{"content":"pT3 N0","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> ddAC/T vs TC (GEP NOT validated) (Plan for NACT)","children":[],"payload":{"lines":"76,77"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Adjuvant ET (AI versus SERM) with Ovarian Suppression (Plan for NAET for good biology LumA)","children":[],"payload":{"lines":"77,78"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> ET duration for 5 years (+/- 5 years per BCI or <a href=\"https://cts5-calculator.com/\">CTS5 Calculator</a>)","children":[],"payload":{"lines":"78,79"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Adjuvant Olaparib in high-risk ER+ HER2- gBRCA1/2 (and PALB2) Stage II and III","children":[],"payload":{"lines":"79,82"}}],"payload":{"lines":"75,82"}}],"payload":{"lines":"60,82"}},{"content":"\n<p data-lines=\"82,83\">STAGE III</p>","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> ddAC/T [TC underperform] [GEP NOT validated] [Consider NACT]","children":[],"payload":{"lines":"83,84"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Adjuvant ET (AI versus SERM) with Ovarian Suppression for 7 to 10 years","children":[],"payload":{"lines":"84,85"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> ABEMACICLIB in high risk patient: pN2/3 OR pN1 with either T3 OR Grade III","children":[],"payload":{"lines":"85,86"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> OLAPARIB in high-risk ER+ HER2- gBRCA1/2 (and PALB2) Stage II and III","children":[],"payload":{"lines":"86,89"}}],"payload":{"lines":"82,89"}},{"content":"\n<p data-lines=\"89,90\">STAGE IV</p>","children":[{"content":"1st line","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> OFS+AI for small volume of disease","children":[],"payload":{"lines":"91,92"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> OFS+AI+CDK4/6, ideally Kisqali (Since <strong>MONALEESA-7</strong> was in premenopasue only)","children":[],"payload":{"lines":"92,93"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> OFS+AI with other CDK4/6 options include Palbociclib and Abemaciclib <strong>PALOMA2</strong> &amp; <strong>MONARCH3</strong>","children":[],"payload":{"lines":"93,94"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> For non-denovo if PIK3CA mut, can consider OFS+Fulvestrant+inavolisib <strong>INAVO120</strong>","children":[],"payload":{"lines":"94,95"}}],"payload":{"lines":"90,95"}},{"content":"2nd line","children":[{"content":"Soft progression on OFS+AI alone","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> OFS+Fulvestrant+CDK4/6 <strong>PALOMA3</strong>, <strong>MONALEESA3</strong> &amp; <strong>MONARCH2</strong>","children":[],"payload":{"lines":"97,98"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> OFS+Affinitor with AI, Tamoxifen or Fulvestrant <strong>BOLERO</strong>, <strong>TAMRAD</strong> &amp; <strong>PrE0102</strong>","children":[],"payload":{"lines":"98,99"}}],"payload":{"lines":"96,99"}},{"content":"Soft progression on OFS+AI+CDK4/6i","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> OFS+Fulvestrant+Abemaciclib (Post prior CDK) <strong>PostMonarch</strong>","children":[],"payload":{"lines":"100,101"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> OFS+Fulvestrant+Ribociclib (Post prior CDK) <strong>MAINTAIN</strong>","children":[],"payload":{"lines":"101,102"}}],"payload":{"lines":"99,102"}},{"content":"PIK3CA mut","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> OFS+Fulvestrant+ Alpelisib <strong>SOLAR1</strong>","children":[],"payload":{"lines":"103,104"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> OFS+Fulvestrant+ Capivasertib <strong>CAPItello-291</strong>","children":[],"payload":{"lines":"104,105"}}],"payload":{"lines":"102,105"}},{"content":"ESR1 mut","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> OFS+Elacestrant <strong>EMERALD</strong>","children":[],"payload":{"lines":"106,107"}}],"payload":{"lines":"105,107"}},{"content":"HBOC/sBRCA/gPALB2","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Olaparib <strong>OlympiAD</strong> &amp; <strong>TBCRC048</strong>","children":[],"payload":{"lines":"108,109"}}],"payload":{"lines":"107,109"}}],"payload":{"lines":"95,109"}},{"content":"3rd line","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Trastuzumab deruxtecan, IHC Ultralow or Low, given after ET <strong>DB06</strong>","children":[],"payload":{"lines":"110,111"}}],"payload":{"lines":"109,111"}},{"content":"4th Line","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Trastuzumab deruxtecan, IHC Low, given after 1 chemo line <strong>DB04</strong>","children":[],"payload":{"lines":"112,113"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Sacituzumab govitecan, regardless of TROP2, given after 1-2 Chemo lines <strong>TROPICS02</strong>","children":[],"payload":{"lines":"113,114"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Datopotamab deruxtecan (DXd), regardless of TROP2, given after 1-2 Chemo lines <strong>Tropion-01</strong>","children":[],"payload":{"lines":"114,115"}}],"payload":{"lines":"111,115"}},{"content":"Further lines","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Paclitaxel","children":[],"payload":{"lines":"116,117"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> nab-Paclitaxel","children":[],"payload":{"lines":"117,118"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Capecitabine","children":[],"payload":{"lines":"118,119"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Eribulin","children":[],"payload":{"lines":"119,120"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Doxil","children":[],"payload":{"lines":"120,121"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Navelbine","children":[],"payload":{"lines":"121,122"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Gemcitabine","children":[],"payload":{"lines":"122,123"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Carboplatin","children":[],"payload":{"lines":"123,124"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Ixabepilone","children":[],"payload":{"lines":"124,125"}}],"payload":{"lines":"115,125"}},{"content":"Tumor Agnostic Indications","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Pembrolizumab in TMB HIGH &gt;= 10mut/Mb","children":[],"payload":{"lines":"126,127"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Pembrolizumab in dMMR/MSI-H","children":[],"payload":{"lines":"127,128"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Dostarlimab in dMMR/MSI-H","children":[],"payload":{"lines":"128,129"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Larotrectinib in NTRK fusions","children":[],"payload":{"lines":"129,130"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Entrectinib in NTRK fusion","children":[],"payload":{"lines":"130,131"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Dabrafenib/trametinib in BRAFV600E mutated","children":[],"payload":{"lines":"131,132"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Selpercatinib in RET fusion","children":[],"payload":{"lines":"132,133"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Neratinib in HER2/ERBB2 mutated","children":[],"payload":{"lines":"133,143"}}],"payload":{"lines":"125,143"}}],"payload":{"lines":"89,143"}}],"payload":{"lines":"41,143"}},{"content":"\n<p data-lines=\"143,144\">Postmenopausal HR+ HER2-</p>","children":[{"content":"STAGE I","children":[{"content":"pT1a N0","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Adjuvant ET is category 2B but still discussed. Absolute DFS and BCSS benefit very small","children":[],"payload":{"lines":"146,147"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Can be considered for 2ry chemoprevention.","children":[],"payload":{"lines":"147,148"}}],"payload":{"lines":"145,148"}},{"content":"pT1b cN0 Grade I","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> TAILORx did not include this population. Can consider MammaPrint on case by case basis","children":[],"payload":{"lines":"149,150"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Adjuvant ET (AI versus SERM). OFS benefit is small","children":[],"payload":{"lines":"150,151"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> ET duration for 5 years (+/- 5 years per BCI or MP)","children":[],"payload":{"lines":"151,152"}}],"payload":{"lines":"148,152"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> pT1b cN0 Grade II/III and pT1c cN0","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Consider Oncotype / Mammaprint (TC) <strong>TAILORx</strong> and <strong>MINDACT</strong>","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> RS ≥26 → Chemotherapy","children":[],"payload":{"lines":"154,155"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> ≤25 or less → No Chemotherapy","children":[],"payload":{"lines":"155,156"}}],"payload":{"lines":"153,156"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Adjuvant ET (AI versus SERM).","children":[],"payload":{"lines":"156,157"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> ET duration for 5 years (+/- 5 years per BCI or MP)","children":[],"payload":{"lines":"157,158"}}],"payload":{"lines":"152,158"}}],"payload":{"lines":"144,158"}},{"content":"STAGE II","children":[{"content":"pT2 N0","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Consider Oncotype / Mammaprint (TC) <strong>TAILORx</strong> and <strong>MINDACT</strong>","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> RS ≥26: Chemotherapy","children":[],"payload":{"lines":"161,162"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> ≤25 or less → No Chemotherapy","children":[],"payload":{"lines":"162,163"}}],"payload":{"lines":"160,163"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Adjuvant ET (AI versus SERM) with Ovarian Suppression [Consider NAET for larger tumors]","children":[],"payload":{"lines":"163,164"}}],"payload":{"lines":"159,164"}},{"content":"pT1 N1, pT2 N1","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Perform Oncotype/Mammaprint [Consider NACT for larger tumors]","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> RS ≥26: Chemotherapy","children":[],"payload":{"lines":"166,167"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> ≤25 or less → No Chemotherapy","children":[],"payload":{"lines":"167,168"}}],"payload":{"lines":"165,168"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Adjuvant ET (AI versus SERM) [Consider NAET for larger tumors]","children":[],"payload":{"lines":"168,169"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> ET duration for 5 years (+/- 5 years per BCI or <a href=\"https://cts5-calculator.com/\">CTS5 Calculator</a>)","children":[],"payload":{"lines":"169,170"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Adjuvant Abemaciclib in high risk patients with N1 and Grade III","children":[],"payload":{"lines":"170,171"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Adjuvant Olaparib in high-risk ER+ HER2- gBRCA1/2 (and PALB2) Stage II and III","children":[],"payload":{"lines":"171,172"}}],"payload":{"lines":"164,172"}},{"content":"pT3 N0","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> ddAC/T vs TC [GEP NOT validated] (Plan for NACT)","children":[],"payload":{"lines":"173,174"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Adjuvant ET (AI versus SERM) (Plan for NAET for good biology LumA)","children":[],"payload":{"lines":"174,175"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> ET duration for 5 years (+/- 5 years per BCI or <a href=\"https://cts5-calculator.com/\">CTS5 Calculator</a>)","children":[],"payload":{"lines":"175,176"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Adjuvant Olaparib in high-risk ER+ HER2- gBRCA1/2 (and PALB2) Stage II and III","children":[],"payload":{"lines":"176,177"}}],"payload":{"lines":"172,177"}}],"payload":{"lines":"158,177"}},{"content":"STAGE III","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> ddAC/T [TC underperform] [GEP NOT validated] [Consider NACT]","children":[],"payload":{"lines":"178,179"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Adjuvant ET (AI versus SERM) for 7 to 10 years","children":[],"payload":{"lines":"179,180"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> ABEMACICLIB in high risk patients with T3 pN1, pN2, pN3","children":[],"payload":{"lines":"180,181"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> OLAPARIB in high-risk ER+ HER2- gBRCA1/2 (and PALB2) Stage II and III","children":[],"payload":{"lines":"181,182"}}],"payload":{"lines":"177,182"}},{"content":"STAGE IV","children":[{"content":"1st line","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> AI for small volume of disease","children":[],"payload":{"lines":"184,185"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> AI+CDK4/6i Palbociclib, Ribociclib OR Abemaciclib <strong>PALOMA2</strong>, <strong>MONALESA2</strong> &amp; <strong>MONARCH3</strong>","children":[],"payload":{"lines":"185,186"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> For non-denovo if PIK3CA mut, can consider Fulvestrant+inavolisib <strong>INAVO120</strong>","children":[],"payload":{"lines":"186,187"}}],"payload":{"lines":"183,187"}},{"content":"2nd line","children":[{"content":"Soft progression on AI alone","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Fulvestrant+CDK4/6i Palbociclib, Ribociclib OR Abemaciclib <strong>PALOMA3</strong>, <strong>MONALEESA3</strong> &amp; <strong>MONARCH2</strong>","children":[],"payload":{"lines":"189,190"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Affinitor with AI, Tamoxifen or Fulvestrant <strong>BOLERO</strong>, <strong>TAMRAD</strong> &amp; <strong>PrE0102</strong>","children":[],"payload":{"lines":"190,191"}}],"payload":{"lines":"188,191"}},{"content":"Soft progression on AI+CDK4/6i","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Fulvestrant+Abemaciclib (Post prior CDK) <strong>PostMonarch</strong>","children":[],"payload":{"lines":"192,193"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Fulvestrant+Ribociclib (Post prior CDK) <strong>MAINTAIN</strong>","children":[],"payload":{"lines":"193,194"}}],"payload":{"lines":"191,194"}},{"content":"PIK3CA mut","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Fulvestrant+ Alpelisib <strong>SOLAR1</strong>","children":[],"payload":{"lines":"195,196"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Fulvestrant+ Capivasertib <strong>CAPItello-291</strong>","children":[],"payload":{"lines":"196,197"}}],"payload":{"lines":"194,197"}},{"content":"ESR1 mut","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Elacestrant <strong>EMERALD</strong>","children":[],"payload":{"lines":"198,199"}}],"payload":{"lines":"197,199"}},{"content":"HBOC/sBRCA/gPALB2","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Olaparib <strong>OlympiAD</strong> &amp; <strong>TBCRC048</strong>","children":[],"payload":{"lines":"200,201"}}],"payload":{"lines":"199,201"}}],"payload":{"lines":"187,201"}},{"content":"3rd line","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Trastuzumab deruxtecan, IHC Ultralow or Low, given after ET <strong>DB06</strong>","children":[],"payload":{"lines":"202,203"}}],"payload":{"lines":"201,203"}},{"content":"4th Line","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Trastuzumab deruxtecan, IHC Low, given after 1 Chemo line <strong>DB04</strong>","children":[],"payload":{"lines":"204,205"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Sacituzumab govitecan, regardless of TROP2, given after 1-2 Chemo lines <strong>TROPICS02</strong>","children":[],"payload":{"lines":"205,206"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Datopotamab deruxtecan (DXd), regardless of TROP2, given after 1-2 Chemo lines <strong>Tropion-01</strong>","children":[],"payload":{"lines":"206,207"}}],"payload":{"lines":"203,207"}},{"content":"Further lines","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Paclitaxel","children":[],"payload":{"lines":"208,209"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> nab-Paclitaxel","children":[],"payload":{"lines":"209,210"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Capecitabine","children":[],"payload":{"lines":"210,211"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Eribulin","children":[],"payload":{"lines":"211,212"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Doxil","children":[],"payload":{"lines":"212,213"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Navelbine","children":[],"payload":{"lines":"213,214"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Gemcitabine","children":[],"payload":{"lines":"214,215"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Carboplatin","children":[],"payload":{"lines":"215,216"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Ixabepilone","children":[],"payload":{"lines":"216,217"}}],"payload":{"lines":"207,217"}},{"content":"Tumor Agnostic Indications","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Pembrolizumab in TMB HIGH &gt;= 10mut/Mb","children":[],"payload":{"lines":"218,219"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Pembrolizumab in dMMR/MSI-H","children":[],"payload":{"lines":"219,220"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Dostarlimab in dMMR/MSI-H","children":[],"payload":{"lines":"220,221"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Larotrectinib in NTRK fusions","children":[],"payload":{"lines":"221,222"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Entrectinib in NTRK fusion","children":[],"payload":{"lines":"222,223"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Dabrafenib/trametinib in BRAFV600E mutated","children":[],"payload":{"lines":"223,224"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Selpercatinib in RET fusion","children":[],"payload":{"lines":"224,225"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Neratinib in HER2/ERBB2 mutated","children":[],"payload":{"lines":"225,233"}}],"payload":{"lines":"217,233"}}],"payload":{"lines":"182,233"}}],"payload":{"lines":"143,233"}},{"content":"\n<p data-lines=\"233,234\">HR- HER2+</p>","children":[{"content":"\n<p data-lines=\"235,236\">STAGE I</p>","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> For pT1a N0, adjuvant Herceptin is rarely used since  category 2B. Can be considered if multifocal disease.","children":[],"payload":{"lines":"236,237"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> For pT1b and pT1c, Upfront surgery then adjuvant Taxol x12 weeks and Herceptin q3Wk x 1 year. <em>APT regimen</em>","children":[],"payload":{"lines":"237,238"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Adjuvant Herceptin to complete 1 year","children":[],"payload":{"lines":"238,239"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> In age 75+, can consider single agent Herceptin <em>RESPECT 2020</em>","children":[],"payload":{"lines":"239,242"}}],"payload":{"lines":"235,242"}},{"content":"\n<p data-lines=\"242,243\">STAGE II</p>","children":[{"content":"Receiving NACT","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Taxotere, Carboplatin, HP <strong>TRYPHEMA</strong>","children":[],"payload":{"lines":"244,245"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Weekly Taxol, HP followed by ddAC <strong>NOAH</strong>","children":[],"payload":{"lines":"245,246"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> For poor ECOG, Can consider TDM1+Pertuzumab <strong>KRISTINE</strong>","children":[],"payload":{"lines":"246,247"}}],"payload":{"lines":"243,247"}},{"content":"Post Receiving NACT","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> If no pCR, TDM-1 to complete a year <strong>KATHRINE</strong>","children":[],"payload":{"lines":"248,249"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> If pCR, adjuvant Herceptin to complete a year. If cN+, adjuvant HP to complete a year <strong>TRYPHEMA</strong>","children":[],"payload":{"lines":"249,250"}}],"payload":{"lines":"247,250"}},{"content":"Adjuvant Therapy without NACT","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Adjuvant Taxotere, Carboplatin, HP <strong>APHINITY</strong>","children":[],"payload":{"lines":"251,252"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> If small N0 T2 &lt;30mm, can consider adjuvant Paclitaxel and Herceptin <strong>APT</strong>","children":[],"payload":{"lines":"252,255"}}],"payload":{"lines":"250,255"}}],"payload":{"lines":"242,255"}},{"content":"\n<p data-lines=\"255,256\">STAGE III</p>","children":[{"content":"Receiving NACT","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Taxotere, Carboplatin, HP <strong>TRYPHEMA</strong>","children":[],"payload":{"lines":"257,258"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Weekly Taxol, HP followed by ddAC <strong>NOAH</strong>","children":[],"payload":{"lines":"258,259"}}],"payload":{"lines":"256,259"}},{"content":"Post Receiving NACT","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> If no pCR, TDM-1 to complete a year <strong>KATHRINE</strong>","children":[],"payload":{"lines":"260,261"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> If pCR, adjuvant Herceptin to complete a year. If cN+, adjuvant HP to complete a year <strong>TRYPHEMA</strong>","children":[],"payload":{"lines":"261,262"}}],"payload":{"lines":"259,262"}},{"content":"Adjuvant Therapy without NACT","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Adjuvant Taxotere, Carboplatin, HP <strong>APHINITY</strong>","children":[],"payload":{"lines":"263,265"}}],"payload":{"lines":"262,265"}}],"payload":{"lines":"255,265"}},{"content":"\n<p data-lines=\"265,266\">STAGE IV</p>","children":[{"content":"1st line","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Docetaxeol OR Paclitaxel with HP → maintenance HP <strong>CLEOPATRA</strong>","children":[],"payload":{"lines":"267,268"}}],"payload":{"lines":"266,268"}},{"content":"2nd line","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Trastuzumab deruxtecan <strong>DB03</strong>","children":[],"payload":{"lines":"269,270"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Capecitabine+Tucatinib+Herceptin <strong>HER2CLIMB01</strong>","children":[],"payload":{"lines":"270,271"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> TDM1+Tucatinib <strong>HER2CLIMB02</strong>","children":[],"payload":{"lines":"271,272"}}],"payload":{"lines":"268,272"}},{"content":"3rd line","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Trastuzumab deruxtecan <strong>DB03</strong>","children":[],"payload":{"lines":"273,274"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Capecitabine+Tucatinib+Herceptin <strong>HER2CLIMB01</strong>","children":[],"payload":{"lines":"274,275"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Margetuximab with chemotherapy <strong>SOPHIA</strong>","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> capecitabine","children":[],"payload":{"lines":"276,277"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> eribulin","children":[],"payload":{"lines":"277,278"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> gemcitabine","children":[],"payload":{"lines":"278,279"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> vinorelbine","children":[],"payload":{"lines":"279,280"}}],"payload":{"lines":"275,280"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Capecitabine+Neratinib typically in HR- HER2+ <strong>NALA</strong>","children":[],"payload":{"lines":"280,281"}}],"payload":{"lines":"272,281"}},{"content":"Further lines (With Herceptin)","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Paclitaxel","children":[],"payload":{"lines":"282,283"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> nab-Paclitaxel","children":[],"payload":{"lines":"283,284"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Capecitabine","children":[],"payload":{"lines":"284,285"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Eribulin","children":[],"payload":{"lines":"285,286"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Doxil","children":[],"payload":{"lines":"286,287"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Navelbine","children":[],"payload":{"lines":"287,288"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Gemcitabine","children":[],"payload":{"lines":"288,289"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Carboplatin","children":[],"payload":{"lines":"289,290"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Ixabepilone","children":[],"payload":{"lines":"290,291"}}],"payload":{"lines":"281,291"}},{"content":"Tumor Agnostic Indications","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Pembrolizumab in TMB HIGH &gt;= 10mut/Mb","children":[],"payload":{"lines":"292,293"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Pembrolizumab in dMMR/MSI-H","children":[],"payload":{"lines":"293,294"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Dostarlimab in dMMR/MSI-H","children":[],"payload":{"lines":"294,295"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Larotrectinib in NTRK fusions","children":[],"payload":{"lines":"295,296"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Entrectinib in NTRK fusion","children":[],"payload":{"lines":"296,297"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Dabrafenib/trametinib in BRAFV600E mutated","children":[],"payload":{"lines":"297,298"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Selpercatinib in RET fusion","children":[],"payload":{"lines":"298,299"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Neratinib in HER2/ERBB2 mutated","children":[],"payload":{"lines":"299,311"}}],"payload":{"lines":"291,311"}}],"payload":{"lines":"265,311"}}],"payload":{"lines":"233,311"}},{"content":"\n<p data-lines=\"311,312\">HR+ HER2+ [Triple POSITIVE]</p>","children":[{"content":"\n<p data-lines=\"314,315\">STAGE I</p>","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> For pT1a N0, adjuvant Herceptin is rarely used since  category 2B. Can be considered if multifocal disease. Adjuvant ET is category 2B but still discussed. Absolute benefit very small, but consider for 2ry chemoprevention.","children":[],"payload":{"lines":"315,316"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> For pT1b and pT1c, Upfront surgery then adjuvant Taxol x12 weeks and Herceptin q3Wk x 1 year. <em>APT regimen</em>","children":[],"payload":{"lines":"316,317"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Adjuvant Herceptin to complete 1 year","children":[],"payload":{"lines":"317,318"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> In age 75+, can consider single agent Herceptin <em>RESPECT 2020</em>","children":[],"payload":{"lines":"318,319"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Adjuvant ET (AI versus SERM)","children":[],"payload":{"lines":"319,320"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Adjuvant Neratinib benefit is likely very small.","children":[],"payload":{"lines":"320,323"}}],"payload":{"lines":"314,323"}},{"content":"\n<p data-lines=\"323,324\">STAGE II</p>","children":[{"content":"Receiving NACT","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Taxotere, Carboplatin, HP <strong>TRYPHEMA</strong>","children":[],"payload":{"lines":"325,326"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Weekly Taxol, HP followed by ddAC <strong>NOAH</strong>","children":[],"payload":{"lines":"326,327"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> For poor ECOG, Can consider TDM1+Pertuzumab <strong>KRISTINE</strong> or Palbociclib+Letrozole+HP <strong>TOUCH</strong>","children":[],"payload":{"lines":"327,328"}}],"payload":{"lines":"324,328"}},{"content":"Post Receiving NACT","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> If no pCR, TDM-1 to complete a year <strong>KATHRINE</strong>","children":[],"payload":{"lines":"329,330"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> If pCR, adjuvant Herceptin to complete a year. If cN+, adjuvant HP to complete a year <strong>TRYPHEMA</strong>","children":[],"payload":{"lines":"330,331"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Adjuvant ET (AI versus SERM) with Ovarian Suppression if premenopausal <strong>SOFT/TEXT</strong>","children":[],"payload":{"lines":"331,332"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Consider Adjuvant Neratinib (Benefit after receiving Kadcyla is unknown) <strong>ExteNET</strong>","children":[],"payload":{"lines":"332,333"}}],"payload":{"lines":"328,333"}},{"content":"Adjuvant Therapy without NACT","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Adjuvant Taxotere, Carboplatin, HP <strong>APHINITY</strong>","children":[],"payload":{"lines":"334,335"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> If small N0 T2 &lt;30mm, can consider adjuvant Paclitaxel and Herceptin <strong>APT</strong>","children":[],"payload":{"lines":"335,336"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Adjuvant ET (AI versus SERM) with Ovarian Suppression if premenopausal <strong>SOFT/TEXT</strong>","children":[],"payload":{"lines":"336,337"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Consider Adjuvant Neratinib (Benefit after receiving Kadcyla is unknown) <strong>ExteNET</strong>","children":[],"payload":{"lines":"337,340"}}],"payload":{"lines":"333,340"}}],"payload":{"lines":"323,340"}},{"content":"\n<p data-lines=\"340,341\">STAGE III</p>","children":[{"content":"Receiving NACT","children":[],"payload":{"lines":"341,342"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Taxotere, Carboplatin, HP <strong>TRYPHEMA</strong>","children":[],"payload":{"lines":"342,343"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Weekly Taxol, HP followed by ddAC <strong>NOAH</strong>","children":[],"payload":{"lines":"343,344"}},{"content":"Post Receiving NACT","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> If no pCR, TDM-1 to complete a year <strong>KATHRINE</strong>","children":[],"payload":{"lines":"345,346"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> If pCR, adjuvant Herceptin to complete a year. If cN+, adjuvant HP to complete a year <strong>TRYPHEMA</strong>","children":[],"payload":{"lines":"346,347"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Adjuvant AI with Ovarian Suppression if premenopausal <strong>SOFT/TEXT</strong>","children":[],"payload":{"lines":"347,348"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Consider Adjuvant Neratinib (Benefit after receiving Kadcyla is unknown) <strong>ExteNET</strong>","children":[],"payload":{"lines":"348,349"}}],"payload":{"lines":"344,349"}},{"content":"Adjuvant Therapy without NACT","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Adjuvant Taxotere, Carboplatin, HP <strong>APHINITY</strong>","children":[],"payload":{"lines":"350,351"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Adjuvant AI with Ovarian Suppression if premenopausal <strong>SOFT/TEXT</strong>","children":[],"payload":{"lines":"351,352"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Adjuvant Neratinib (Benefit after receiving Kadcyla is unknown) <strong>ExteNET</strong>","children":[],"payload":{"lines":"352,355"}}],"payload":{"lines":"349,355"}}],"payload":{"lines":"340,355"}},{"content":"\n<p data-lines=\"355,356\">STAGE IV</p>","children":[{"content":"1st line","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Docetaxeol OR Paclitaxel with HP → maintenance ET + HP <strong>CLEOPATRA</strong> &amp; <strong>PERTAIN</strong>","children":[],"payload":{"lines":"357,358"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Docetaxeol OR Paclitaxel with HP → maintenance ET + HP + CDK4/6i <strong>PATINA</strong>","children":[],"payload":{"lines":"358,359"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> ET + HP <strong>SYSUCC002</strong>","children":[],"payload":{"lines":"359,360"}}],"payload":{"lines":"356,360"}},{"content":"2nd line","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Trastuzumab deruxtecan <strong>DB03</strong>","children":[],"payload":{"lines":"361,362"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Capecitabine+Tucatinib+Herceptin <strong>HER2CLIMB01</strong>","children":[],"payload":{"lines":"362,363"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> TDM1+Tucatinib <strong>HER2CLIMB02</strong>","children":[],"payload":{"lines":"363,364"}}],"payload":{"lines":"360,364"}},{"content":"3rd line","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Trastuzumab deruxtecan if not used before <strong>DB03</strong>","children":[],"payload":{"lines":"365,366"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Capecitabine+Tucatinib+Herceptin if not used before <strong>HER2CLIMB01</strong>","children":[],"payload":{"lines":"366,367"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Margetuximab with chemotherapy <strong>SOPHIA</strong>","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> capecitabine","children":[],"payload":{"lines":"368,369"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> eribulin","children":[],"payload":{"lines":"369,370"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> gemcitabine","children":[],"payload":{"lines":"370,371"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> vinorelbine","children":[],"payload":{"lines":"371,372"}}],"payload":{"lines":"367,372"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Capecitabine+Neratinib typically in HR- HER2+ <strong>NALA</strong>","children":[],"payload":{"lines":"372,373"}}],"payload":{"lines":"364,373"}},{"content":"Further lines (With Herceptin)","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Paclitaxel","children":[],"payload":{"lines":"374,375"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> nab-Paclitaxel","children":[],"payload":{"lines":"375,376"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Capecitabine","children":[],"payload":{"lines":"376,377"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Eribulin","children":[],"payload":{"lines":"377,378"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Doxil","children":[],"payload":{"lines":"378,379"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Navelbine","children":[],"payload":{"lines":"379,380"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Gemcitabine","children":[],"payload":{"lines":"380,381"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Carboplatin","children":[],"payload":{"lines":"381,382"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Ixabepilone","children":[],"payload":{"lines":"382,383"}}],"payload":{"lines":"373,383"}},{"content":"Tumor Agnostic Indications","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Pembrolizumab in TMB HIGH &gt;= 10mut/Mb","children":[],"payload":{"lines":"384,385"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Pembrolizumab in dMMR/MSI-H","children":[],"payload":{"lines":"385,386"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Dostarlimab in dMMR/MSI-H","children":[],"payload":{"lines":"386,387"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Larotrectinib in NTRK fusions","children":[],"payload":{"lines":"387,388"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Entrectinib in NTRK fusion","children":[],"payload":{"lines":"388,389"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Dabrafenib/trametinib in BRAFV600E mutated","children":[],"payload":{"lines":"389,390"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Selpercatinib in RET fusion","children":[],"payload":{"lines":"390,391"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Neratinib in HER2/ERBB2 mutated","children":[],"payload":{"lines":"391,404"}}],"payload":{"lines":"383,404"}}],"payload":{"lines":"355,404"}}],"payload":{"lines":"311,404"}},{"content":"\n<p data-lines=\"404,405\">HR- HER2- [Triple NEGATIVE]</p>","children":[{"content":"STAGE I","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> For cT1a N0, upfront surgery. Benefit of adjuvant Chemotherapy is very minimal","children":[],"payload":{"lines":"406,407"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Definitive Surgery followed by Chemotherapy","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Adjuvant Docetaxel Cytoxan x 4 CYCLES","children":[],"payload":{"lines":"408,409"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Added benefit of ddAC/T over TC is likely very small <em>ABC Analysis 2024</em>","children":[],"payload":{"lines":"409,410"}}],"payload":{"lines":"407,410"}}],"payload":{"lines":"405,410"}},{"content":"STAGE II","children":[{"content":"Neoadjuvant Therapy","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Taxol (Weekly) followed by ddAC <em>ABC</em>","children":[],"payload":{"lines":"412,413"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Taxol Carboplatin (Weekly) Pembro then dd Pembro <em>KEYNOTE-522</em>","children":[],"payload":{"lines":"413,414"}}],"payload":{"lines":"411,414"}},{"content":"Post Neoadjuvant Therapy","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Adjuvant Pembrolizumab to complete a year","children":[],"payload":{"lines":"415,416"}},{"content":"Post Neoadjuvant Therapy","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> If no pCR, Capecitabine 1000 mg/m2 D1-14 of 21D CYCLE x 8 CYCLES <em>CREATE-x</em>","children":[],"payload":{"lines":"417,418"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> If no pCR, gBRCA1/2 (and PALB2), adjuvant Olaparib <em>OlympiA</em>","children":[],"payload":{"lines":"418,419"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> For high risk patients with pCR, consider adjuvant capecitabine 650 mg/m2 D1-28 of 28D CYCLE x 12 CYCLES <strong>SYSUCC-001</strong>","children":[],"payload":{"lines":"419,420"}}],"payload":{"lines":"416,420"}}],"payload":{"lines":"414,420"}}],"payload":{"lines":"410,420"}},{"content":"STAGE III","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Taxol Carboplatin (Weekly) Pembro then dd Pembro (KN522)","children":[],"payload":{"lines":"421,422"}},{"content":"Post NACT","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Adjuvant Pembrolizumab 200mg IV q21D post KN522 for 9 CYCLES","children":[],"payload":{"lines":"423,424"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> If no pCR, Capecitabine 1250 mg/m2 D1-14 of 21D CYCLE x 8 CYCLES (CREATE-x)","children":[],"payload":{"lines":"424,425"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> If pCR, Capecitabine 650 mg/m2 D1-28 of 28D CYCLE x 12 CYCLES (SYSUCC-001)","children":[],"payload":{"lines":"425,426"}}],"payload":{"lines":"422,426"}}],"payload":{"lines":"420,426"}},{"content":"STAGE IV","children":[{"content":"1st line","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Paclitaxel OR Abraxane OR CarboGem. Add Pembro if 22C3+ <strong>KN355</strong>","children":[],"payload":{"lines":"428,429"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Olaparib OR Talzaporib for germline BRCA1/2 <strong>OlympiA</strong> and for somatic/germline PALB2 and somatic BRCA1/2 <strong>TBCRC048</strong>","children":[],"payload":{"lines":"429,430"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Capecitabine 1000mg/m2 for low volume disease","children":[],"payload":{"lines":"430,431"}}],"payload":{"lines":"427,431"}},{"content":"2nd line","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Trastuzumab deruxtecan, IHC Low, given after 1 Chemo line <strong>DB04</strong>","children":[],"payload":{"lines":"432,433"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Sacituzumab govitecan, regardless of TROP2, given after 1-2 Chemo lines <strong>TROPICS02</strong>","children":[],"payload":{"lines":"433,434"}}],"payload":{"lines":"431,434"}},{"content":"3rd line","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Sacituzumab govitecan, regardless of TROP2, given after 1-2 Chemo lines <strong>TROPICS02</strong>","children":[],"payload":{"lines":"435,436"}}],"payload":{"lines":"434,436"}},{"content":"Further lines","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Paclitaxel","children":[],"payload":{"lines":"437,438"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> nab-Paclitaxel","children":[],"payload":{"lines":"438,439"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Capecitabine","children":[],"payload":{"lines":"439,440"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Eribulin","children":[],"payload":{"lines":"440,441"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Doxil","children":[],"payload":{"lines":"441,442"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Navelbine","children":[],"payload":{"lines":"442,443"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Gemcitabine","children":[],"payload":{"lines":"443,444"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Carboplatin","children":[],"payload":{"lines":"444,445"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Ixabepilone","children":[],"payload":{"lines":"445,446"}}],"payload":{"lines":"436,446"}},{"content":"Tumor Agnostic Indications","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Pembrolizumab in TMB HIGH &gt;= 10mut/Mb","children":[],"payload":{"lines":"447,448"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Pembrolizumab in dMMR/MSI-H","children":[],"payload":{"lines":"448,449"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Dostarlimab in dMMR/MSI-H","children":[],"payload":{"lines":"449,450"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Larotrectinib in NTRK fusions","children":[],"payload":{"lines":"450,451"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Entrectinib in NTRK fusion","children":[],"payload":{"lines":"451,452"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Dabrafenib/trametinib in BRAFV600E mutated","children":[],"payload":{"lines":"452,453"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Selpercatinib in RET fusion","children":[],"payload":{"lines":"453,454"}},{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Neratinib in HER2/ERBB2 mutated","children":[],"payload":{"lines":"454,456"}}],"payload":{"lines":"446,456"}}],"payload":{"lines":"426,456"}}],"payload":{"lines":"404,456"}}],"payload":{"lines":"0,456"}}, {"initialExpandLevel":2,"maxWidth":250});
})();
</script>
</body>
</html>
